GenSight Biologics Reports its Cash Position as of September 30, 2017

Paris, France, October 26, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today reported its cash position as of September 30, 2017.

Please find the full PDF press release attached.

Contacts

GenSight Biologics Thomas Gidoin Chief Financial Officer ir@gensight-biologics.com +33 (0)1 76 21 72 20

NewCap Investor Relations Florent Alba gensight@newcap.eu +33 (0)1 44 71 98 55

Rooney Partners Media Relations Marion Janic mjanic@rooneyco.com +1-212-223-4017

---

Source: GenSight Biologics